P3-132: A Phase II trial of docetaxel, oxaliplatin and bevacizumab as first–line therapy of unresectable, locally advanced or recurrent and/or metastatic (Stage IIIB/IV) non–small cell lung cancer (NSCLC)– initial safety analysis

Autor:	Robert Asbury, Luis E. Raez, Timothy Webb, Nicholas Sarlis, Edgardo S. Santos, William Babcock, M. Karr, Rogelio Brito, Khaled A. Tolba
Rok vydání:	2007
Předmět:	Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Bevacizumab business.industry Locally advanced non-small cell lung cancer (NSCLC) Stage iiib medicine.disease First line therapy Internal medicine medicine business Docetaxel/oxaliplatin medicine.drug
Zdroj:	Journal of Thoracic Oncology. 2:S735
ISSN:	1556-0864
DOI:	10.1097/01.jto.0000284107.34082.1b
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c0d1f4e596bdd10329929a41973d87e https://doi.org/10.1097/01.jto.0000284107.34082.1b Zobrazit plný text záznamu